A Phase 1 interventional study of Ubrogepant and Erenumab in Migraine, sponsored by Allergan. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-03-10.
Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.
Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1, and was the 6th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
By country, each count listing its studies:
ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 507 across the 14 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 37th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 1, and was the 27th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
2 of the studies testing ubrogepant in Migraine Disorders that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05125302Phase 3AbbVieStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | 2027-05 |
| NCT06417775Phase 3AbbVieStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ubrogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention B: Single subcutaneous (SC) injection of erenumab 140 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
Drug: Ubrogepant · Drug: Erenumab
Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention C: Two SC injections of galcanezumab 120 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
Drug: Ubrogepant · Drug: Galcanezumab
Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].
Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].
2 SC injections of galcanezumab 120 mg \[Intervention C\].
Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 2: AUC0-t for Ubrogepant Alone and in Combination With Galcanezumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) for Ubrogepant Alone and in Combination With Erenumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 2: AUC0-∞ for Ubrogepant Alone and in Combination With Galcanezumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 1: Time of Maximum Plasma Drug Concentration (Tmax) for Ubrogepant Alone and in Combination With Erenumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 2: Tmax for Ubrogepant Alone and in Combination With Galcanezumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 1: Terminal Elimination Rate Constant (λz) for Ubrogepant Alone and in Combination With Erenumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 2: λz for Ubrogepant Alone and in Combination With Galcanezumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 1: Terminal Elimination Half-life (T½) for Ubrogepant Alone and in Combination With Erenumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 2: T½ for Ubrogepant Alone and in Combination With Galcanezumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 1: Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for Ubrogepant Alone and in Combination With Erenumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 2: CL/F for Ubrogepant Alone and in Combination With Galcanezumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 1: Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Ubrogepant Alone in Combination With Erenumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Part 2: Vz/F for Ubrogepant Alone in Combination With Galcanezumab
Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Number of Participants Who Had Potentially Clinically Significant (PCS) Postbaseline Vital Sign Values
Vital Signs included assessments of Blood Pressure, Pulse Rate, Weight, Respiratory Rate and Temperature. The investigator determined if the postbaseline Vital Sign values were potentially clinically significant using the Vital Sign PCS Criteria in the Statistical Analysis Plan (SAP).
Time frame: End of Dosing (EOD): Within 7 days of Day 16 or at the time of early termination (Up to Day 16)
Number of Participants Who Had PCS Postbaseline Laboratory Values
Laboratory assessments included Chemistry, Hematology and Urinalysis tests. The investigator determined if the postbaseline laboratory results were potentially clinically significant using the Clinical Laboratory PCS Criteria in the SAP. Assessments of Chemistry only were collected at the Final Follow-up Visit
Time frame: EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16); Follow-up Visit 30 days after last dose (Up to Day 45 +/-3 days)
Number of Participants Who Had PCS Postbaseline Physical Examination Values
Time frame: EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16)
Number of Participants Who Had PCS Postbaseline Electrocardiogram (ECG) Values
A standard 12-lead ECG was performed. The investigator determined if the ECG postbaseline values were potentially clinically significant using the ECG PCS Criteria in the SAP.
Time frame: EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16)
Number of Participants With Adverse Events (AEs) by Severity, Related AEs and AEs Leading to Discontinuation
An AE is any untoward medical occurrence in a patient or a participant using an investigational drug, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The investigator determined if the AE was causally related to treatment. The investigator determined if the severity of the AE was Mild (transient with minimal intervention that does not interfere with usual activities), Moderate ( usually alleviated with an intervention, interferes with usual activities causing discomfort but does not cause permanent harm) or Severe (interrupts usual activities, affects clinical status or requires intensive intervention).
Time frame: First dose to within 30 days after last dose (Up to Day 45 +/-3 days)
| Milestone | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
| Milestone | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) |
|---|---|---|
| Started | 19 | 20 |
| Completed | 19 | 20 |
| Not completed | 0 | 0 |
| Milestone | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) |
|---|---|---|
| Started | 19 | 19 |
| Completed | 19 | 19 |
| Not completed | 0 | 0 |
| nanogram*hour/milliliter (ng*h/mL) | Part 1: Ubrogepant Alone | Part 1: Ubrogepant in Combination With Erenumab |
|---|---|---|
| Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab | 1841.42 ± 490.17 | 1959.96 ± 639.51 |
| ng*h/mL | Part 2: Ubrogepant Alone | Part 2: Ubrogepant in Combination With Galcanezumab |
|---|---|---|
| Part 2: AUC0-t for Ubrogepant Alone and in Combination With Galcanezumab | 1700.31 ± 913.42 | 1758.05 ± 1033.44 |
| ng*h/mL | Part 1: Ubrogepant Alone | Part 1: Ubrogepant in Combination With Erenumab |
|---|---|---|
| Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) for Ubrogepant Alone and in Combination With Erenumab | 1878.25 ± 497.82 | 1993.40 ± 639.22 |
| ng*h/mL | Part 2: Ubrogepant Alone | Part 2: Ubrogepant in Combination With Galcanezumab |
|---|---|---|
| Part 2: AUC0-∞ for Ubrogepant Alone and in Combination With Galcanezumab | 1732.22 ± 928.06 | 1793.74 ± 1057.02 |
| ng/mL | Part 1: Ubrogepant Alone | Part 1: Ubrogepant in Combination With Erenumab |
|---|---|---|
| Part 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab | 459.32 ± 168.56 | 486.80 ± 201.52 |
| ng/mL | Part 2: Ubrogepant Alone | Part 2: Ubrogepant in Combination With Galcanezumab |
|---|---|---|
| Part 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab | 415.34 ± 225.64 | 375.12 ± 152.08 |
| hour | Part 1: Ubrogepant Alone | Part 1: Ubrogepant in Combination With Erenumab |
|---|---|---|
| Part 1: Time of Maximum Plasma Drug Concentration (Tmax) for Ubrogepant Alone and in Combination With Erenumab | 1.50 (1.00 to 3.00) | 1.48 (0.50 to 3.02) |
| hour | Part 2: Ubrogepant Alone | Part 2: Ubrogepant in Combination With Galcanezumab |
|---|---|---|
| Part 2: Tmax for Ubrogepant Alone and in Combination With Galcanezumab | 1.50 (1.00 to 6.00) | 1.50 (0.98 to 6.00) |
| 1/hour | Part 1: Ubrogepant Alone | Part 1: Ubrogepant in Combination With Erenumab |
|---|---|---|
| Part 1: Terminal Elimination Rate Constant (λz) for Ubrogepant Alone and in Combination With Erenumab | 0.136 ± 0.025 | 0.156 ± 0.034 |
| 1/hour | Part 2: Ubrogepant Alone | Part 2: Ubrogepant in Combination With Galcanezumab |
|---|---|---|
| Part 2: λz for Ubrogepant Alone and in Combination With Galcanezumab | 0.150 ± 0.053 | 0.165 ± 0.056 |
| hour | Part 1: Ubrogepant Alone | Part 1: Ubrogepant in Combination With Erenumab |
|---|---|---|
| Part 1: Terminal Elimination Half-life (T½) for Ubrogepant Alone and in Combination With Erenumab | 5.26 ± 1.00 | 4.62 ± 0.94 |
| hour | Part 2: Ubrogepant Alone | Part 2: Ubrogepant in Combination With Galcanezumab |
|---|---|---|
| Part 2: T½ for Ubrogepant Alone and in Combination With Galcanezumab | 5.04 ± 1.47 | 4.60 ± 1.35 |
| liter/hour | Part 1: Ubrogepant Alone | Part 1: Ubrogepant in Combination With Erenumab |
|---|---|---|
| Part 1: Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for Ubrogepant Alone and in Combination With Erenumab | 57.35 ± 17.20 | 54.74 ± 16.27 |
| liter/hour | Part 2: Ubrogepant Alone | Part 2: Ubrogepant in Combination With Galcanezumab |
|---|---|---|
| Part 2: CL/F for Ubrogepant Alone and in Combination With Galcanezumab | 72.90 ± 38.07 | 68.94 ± 28.12 |
| liter | Part 1: Ubrogepant Alone | Part 1: Ubrogepant in Combination With Erenumab |
|---|---|---|
| Part 1: Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Ubrogepant Alone in Combination With Erenumab | 436.95 ± 158.11 | 375.84 ± 161.42 |
| liter | Part 2: Ubrogepant Alone | Part 2: Ubrogepant in Combination With Galcanezumab |
|---|---|---|
| Part 2: Vz/F for Ubrogepant Alone in Combination With Galcanezumab | 568.66 ± 497.92 | 449.26 ± 213.84 |
Vital Signs included assessments of Blood Pressure, Pulse Rate, Weight, Respiratory Rate and Temperature. The investigator determined if the postbaseline Vital Sign values were potentially clinically significant using the Vital Sign PCS Criteria in the Statistical Analysis Plan (SAP).
| Participants | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) |
|---|---|---|
| Number of Participants Who Had Potentially Clinically Significant (PCS) Postbaseline Vital Sign Values | 0 | 0 |
Laboratory assessments included Chemistry, Hematology and Urinalysis tests. The investigator determined if the postbaseline laboratory results were potentially clinically significant using the Clinical Laboratory PCS Criteria in the SAP. Assessments of Chemistry only were collected at the Final Follow-up Visit
| Participants | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) |
|---|---|---|
| Hematology; EOD | 0 | 1 |
| Chemistry; EOD | 0 | 0 |
| Chemistry; Follow-up Visit | 1 | 1 |
| Urinalysis; EOD | 1 | 0 |
No measurements were reported for this outcome.
A standard 12-lead ECG was performed. The investigator determined if the ECG postbaseline values were potentially clinically significant using the ECG PCS Criteria in the SAP.
| Participants | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) |
|---|---|---|
| Number of Participants Who Had PCS Postbaseline Electrocardiogram (ECG) Values | 0 | 0 |
An AE is any untoward medical occurrence in a patient or a participant using an investigational drug, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The investigator determined if the AE was causally related to treatment. The investigator determined if the severity of the AE was Mild (transient with minimal intervention that does not interfere with usual activities), Moderate ( usually alleviated with an intervention, interferes with usual activities causing discomfort but does not cause permanent harm) or Severe (interrupts usual activities, affects clinical status or requires intensive intervention).
| Participants | Part 1: Intervention A (Ubrogepant) | Part 1: Intervention B (Erenumab) | Part 1: Intervention D (Ubrogepant) | Part 2: Intervention A (Ubrogepant) | Part 2: Intervention C (Galcanezumab) | Part 2: Intervention D (Ubrogepant) |
|---|---|---|---|---|---|---|
| All AEs | 7 | 8 | 7 | 2 | 3 | 4 |
| AEs by Severity: Mild | 7 | 8 | 6 | 2 | 3 | 4 |
| AEs by Severity: Moderate | 0 | 0 | 0 | 0 | 0 | 0 |
| AEs by Severity: Severe | 0 | 0 | 1 | 0 | 0 | 0 |
| Related AEs | 2 | 7 | 5 | 0 | 3 | 3 |
| AEs Leading to Discontinuation | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over First dose to within 30 days after last dose (Up to Day 45 +/-3 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Intervention A (Ubrogepant) | 0/20 (0%) | 0/20 (0%) | 7/20 (35%) |
| Part 1: Intervention B (Erenumab) | 0/19 (0%) | 0/19 (0%) | 8/19 (42.1%) |
| Part 1: Intervention D (Ubrogepant) | 0/19 (0%) | 0/19 (0%) | 7/19 (36.8%) |
| Part 2; Intervention A (Ubrogepant) | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| Part 2: Intervention C (Galcanezumab) | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Part 2: Intervention D (Ubrogepant) | 0/19 (0%) | 0/19 (0%) | 4/19 (21.1%) |
| Event | Part 1: Intervention A (Ubrogepant) | Part 1: Intervention B (Erenumab) | Part 1: Intervention D (Ubrogepant) | Part 2; Intervention A (Ubrogepant) | Part 2: Intervention C (Galcanezumab) | Part 2: Intervention D (Ubrogepant) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/20 | 6/19 | 1/19 | 0/20 | 3/20 | 0/19 |
| Puncture site painGeneral disorders | 3/20 | 0/19 | 0/19 | 2/20 | 0/20 | 0/19 |
| ConstipationGastrointestinal disorders | 0/20 | 1/19 | 2/19 | 0/20 | 0/20 | 0/19 |
| Abdominal pain upperGastrointestinal disorders | 0/20 | 0/19 | 2/19 | 0/20 | 0/20 | 1/19 |
| NauseaGastrointestinal disorders | 0/20 | 0/19 | 2/19 | 0/20 | 0/20 | 0/19 |
| DizzinessNervous system disorders | 0/20 | 0/19 | 1/19 | 0/20 | 0/20 | 2/19 |
| FlatulenceGastrointestinal disorders | 0/20 | 1/19 | 0/19 | 0/20 | 0/20 | 0/19 |
| Abdominal painGastrointestinal disorders | 0/20 | 0/19 | 1/19 | 0/20 | 0/20 | 0/19 |
| VomitingGastrointestinal disorders | 0/20 | 0/19 | 1/19 | 1/20 | 0/20 | 0/19 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/20 | 1/19 | 0/19 | 0/20 | 0/20 | 0/19 |
Safety population included all participants who received/took at least 1 administration of study intervention in Part 1 or Part 2.
| Age, Customized(years) | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) | Total |
|---|---|---|---|
| Mean | 32.2 (20 to 50) | 38.4 (18 to 50) | 35.3 (18 to 50) |
| Sex: Female, Male(Participants) | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) | Total |
|---|---|---|---|
| Female | 10 | 12 | 22 |
| Male | 10 | 8 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 4 |
| Not Hispanic or Latino | 20 | 16 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 9 | 16 |
| White | 12 | 11 | 23 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part 1 (Intervention A Then B Then D) | Part 2 (Intervention A Then C Then D) | Total |
|---|---|---|---|
| North America | 20 | 20 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2019 to primary completion in Dec 2019, 2 months.
Results were first posted in Mar 2021, 1 year 2 months after primary completion.
Of 39 industry-sponsored phase 1 interventional studies under Migraine Disorders, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 2 months is below that.
Counting every sponsor, half of 53 studies reached it within 6 months; a quarter within 2 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ubrogepant · Erenumab · Galcanezumab